Prospective CERAD Neuropsychological Assessment in Patients With Multiple System Atrophy.
CERAD neuropsychological assessment battery
executive dysfunction
multiple system atrophy (MSA)
neuropsychology
trail making test (TMT)
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
02
2022
accepted:
06
06
2022
entrez:
5
8
2022
pubmed:
6
8
2022
medline:
6
8
2022
Statut:
epublish
Résumé
The objective of the study was to characterize the pattern of cognitive dysfunction in patients with multiple system atrophy (MSA) applying a standardized neuropsychological assessment. A total of 20 patients with the diagnosis of probable or possible MSA were enrolled for neuropsychological assessment applying the CERAD plus battery. All patients were tested at baseline and 14/20 patients received additional follow-up assessments (median follow-up of 24 months). Additionally, relationship between cortical thickness values/subcortical gray matter volumes and CERAD subitems was evaluated at baseline in a subgroup of 13/20 patients. Trail Making Test (TMT) was the most sensitive CERAD item at baseline with abnormal performance (z-score < -1.28) in one or both pathological TMT items (TMT-A, TMT-B) in 60% of patients with MSA. Additionally, there was a significant inverse correlation between the volume of the left and the right accumbens area and the TMT A item after adjusting for age (left side:
Identifiants
pubmed: 35928131
doi: 10.3389/fneur.2022.881369
pmc: PMC9344909
doi:
Types de publication
Journal Article
Langues
eng
Pagination
881369Informations de copyright
Copyright © 2022 Maass, Hermann, Varges, Nuhn, van Riesen, Jamous, Focke, Hewitt, Leha, Bähr and Zerr.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur J Neurol. 2009 Oct;16(10):1144-50
pubmed: 19486137
Front Aging Neurosci. 2020 Nov 27;12:591666
pubmed: 33328969
Stud Health Technol Inform. 2000;77:195-9
pubmed: 11187541
Neuroimage. 1999 Feb;9(2):179-94
pubmed: 9931268
J Neural Transm (Vienna). 2020 Jun;127(6):925-934
pubmed: 32172473
Arch Clin Neuropsychol. 2013 Mar;28(2):189-98
pubmed: 23299183
Neurobiol Aging. 2019 Apr;76:194-200
pubmed: 30739076
J Neurol. 2020 Sep;267(9):2754-2770
pubmed: 32436100
Mov Disord. 2014 Jun;29(7):857-67
pubmed: 24753321
J Neural Transm (Vienna). 2013 Apr;120(4):613-8
pubmed: 23462799
Neuroimage. 1999 Feb;9(2):195-207
pubmed: 9931269
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Parkinsonism Relat Disord. 2021 Aug;89:155-161
pubmed: 34303202
Eur Arch Psychiatry Clin Neurosci. 2015 Aug;265(5):407-17
pubmed: 25555899
Neurology. 1989 Sep;39(9):1159-65
pubmed: 2771064
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
Parkinsonism Relat Disord. 2015 Oct;21(10):1273-7
pubmed: 26305998
J Neural Transm (Vienna). 2020 Jul;127(7):1031-1039
pubmed: 32367182
Dement Geriatr Cogn Dis Extra. 2014 Aug 27;4(2):322-34
pubmed: 25298776
J Clin Exp Neuropsychol. 2000 Aug;22(4):518-28
pubmed: 10923061
Eur Neurol. 2014;72(5-6):349-59
pubmed: 25322750
Mov Disord. 2003 Jul;18(7):738-50
pubmed: 12815652
Mov Disord. 2014 Jun;29(7):897-903
pubmed: 24817690
Front Neurol. 2020 Nov 23;11:537360
pubmed: 33329297
J Neural Transm (Vienna). 2019 Nov;126(11):1437-1445
pubmed: 31432258
J Neurol Neurosurg Psychiatry. 2000 Sep;69(3):313-8
pubmed: 10945805
Lancet Neurol. 2005 Oct;4(10):605-10
pubmed: 16168928
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
Arq Neuropsiquiatr. 2000 Sep;58(3B):826-9
pubmed: 11018818
PLoS One. 2016 Oct 31;11(10):e0165719
pubmed: 27798694
Ann Clin Transl Neurol. 2020 Feb;7(2):219-228
pubmed: 32031752
Mov Disord. 2017 Mar;32(3):405-413
pubmed: 27859650
Mov Disord. 2006 Jun;21(6):772-6
pubmed: 16475154
Parkinsonism Relat Disord. 2020 Jan;70:67-73
pubmed: 31881520